Please book an appointment with the best Gynecologist in Lahore , Karachi, Islamabad, and all major cities of Pakistan through InstaCare , or call our helpline at 03171777509 to find a verified doctor for your disease.
Stimulation of autocrine GLP-1 and CCK
GLP-1 Receptor Agonist Market Key Takeaways Eli Lilly and Company, Sanofi, Novo-Nordisk A/S, AstraZeneca, Pfizer, Inc., Amgen, Inc., Innovent Biologics, Inc., PegBio Co., Ltd., Sun Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH Increasing prevalence of chronic diseases such as diabetes and obesity Increasing R&D activities for developing novel therapeutics Formulation advancements of oral GLP-1 receptor agonists Adverse effects associated with few GLP-1 agonist drugs Product recalls by market players With the increasing prevalence of diabetes and obesity, GLP-1 receptor agonists have become popular due to their effectiveness in glycemic control and weight reduction, offering a dual benefit in managing type 2 diabetes mellitus (T2DM)
Drug companies are cashing in while they can Novo Nordisk, the Danish creator of Ozempic and Wegovy, made $4.8 billion from the drugs in the third quarter of 2023 alone, boosting the economy in Denmark and leading to lower interest rates for ordinary Danes
